This content is PDF only. Please click on the PDF icon to access.
To the editor: Dr. Schwartz's article on the tolbutamide controversy (ANNALS 75:303-306, 1971) is revealing in its presentation of the moral dilemmas that face the physician-researcher. After analyzing the methods of the UGDP study, as well as the madness of its critics, he asks the reader to consider that neither the pitfalls in the study nor the rhetorical skills of its opponents could "erase the impact of what is reproduced in Figure 1." This figure shows that the cumulative mortality rate in the tolbutamide therapy group was the greatest of all groups in the study. Dr. Schwartz states that after
CHERNOFF A. Tolbutamide and Truth. Ann Intern Med. ;75:807. doi: 10.7326/0003-4819-75-5-807_1
Download citation file:
Published: Ann Intern Med. 1971;75(5):807.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use